[{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Financing","leadProduct":"PrabotulinumtoxinA","moa":"SNAP-25","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"AEON Biopharma \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"SNAP-25","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"SNAP-25","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Prabotulinumtoxin A","moa":"SNAP25","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Financing","leadProduct":"PrabotulinumtoxinA","moa":"SNAP-25","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"Ach","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Priveterra Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Merger","leadProduct":"PrabotulinumtoxinA","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0.47999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.47999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"AEON Biopharma \/ Priveterra Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Priveterra Acquisition Corp."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"PrabotulinumtoxinA","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"AEON Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"PrabotulinumtoxinA","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"AEON Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Priveterra Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Merger","leadProduct":"PrabotulinumtoxinA","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.28000000000000003,"dosageForm":"Injectable\/Injection","sponsorNew":"AEON Biopharma \/ Priveterra Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Priveterra Acquisition Corp."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Priveterra Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Merger","leadProduct":"PrabotulinumtoxinA","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AEON Biopharma \/ Priveterra Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Priveterra Acquisition Corp."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Private Placement","leadProduct":"PrabotulinumtoxinA","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"AEON Biopharma \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Prabotulinumtoxin A","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Prabotulinumtoxin A","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AEON Biopharma \/ PPD","highestDevelopmentStatusID":"14","companyTruncated":"AEON Biopharma \/ PPD"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Prabotulinumtoxin A","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"AEON Biopharma \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by AEON Biopharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : ABP-450 (prabotulinumtoxin A) is an investigational, 900 kDa botulinum toxin type A complex, which acts as a SNAP inhibitor indicated for the treatment of cervical dystonia.

                          Brand Name : ABP-450

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 30, 2024

                          Lead Product(s) : Prabotulinumtoxin A

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : ABP-450 (prabotulinumtoxin A) is an investigational, 900 kDa botulinum toxin type A complex, which acts as a SNAP inhibitor indicated for the treatment of cervical dystonia.

                          Brand Name : ABP-450

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          July 09, 2024

                          Lead Product(s) : Prabotulinumtoxin A

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : PPD

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : ABP-450 is a 900-kDa botulinum toxin type A complex, which acts as a SNAP inhibitor. It is being evaluated for the treatment of chronic migraine.

                          Brand Name : ABP-450

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 03, 2024

                          Lead Product(s) : Prabotulinumtoxin A

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum. It is being evaluated for episodic and chronic migraine.

                          Brand Name : ABP-450

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          March 19, 2024

                          Lead Product(s) : PrabotulinumtoxinA

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The proceeds will support late-stage clinical development of ABP-450, a botulinum toxin type-A complex for episodic migraine treatment.

                          Brand Name : ABP-450

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          March 19, 2024

                          Lead Product(s) : PrabotulinumtoxinA

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Daewoong Pharmaceutical

                          Deal Size : $15.0 million

                          Deal Type : Private Placement

                          blank

                          06

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum. It is being evaluated for the treatment of episodic and chronic migraine.

                          Brand Name : ABP-450

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          December 12, 2023

                          Lead Product(s) : PrabotulinumtoxinA

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum. AEON recently completed Phase 2 of ABP-450 for cervical dystonia and has an ongoing Phase 2 of ABP-450 for both chronic and ep...

                          Brand Name : ABP-450

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 19, 2023

                          Lead Product(s) : PrabotulinumtoxinA

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The combined company will focus on the development of ABP-450 (prabotulinumtoxinA) injection, the same botulinum toxin approved and marketed for an aesthetic indication, to treat debilitating medical conditions in neurology.

                          Brand Name : ABP-450

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          July 21, 2023

                          Lead Product(s) : PrabotulinumtoxinA

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Priveterra Acquisition Corp.

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          09

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The combined company will focus on the development of ABP-450 (prabotulinumtoxinA) injection, the same botulinum toxin approved and marketed for an aesthetic indication, to treat debilitating medical conditions in neurology.

                          Brand Name : ABP-450

                          Molecule Type : Large molecule

                          Upfront Cash : $276.0 million

                          July 11, 2023

                          Lead Product(s) : PrabotulinumtoxinA

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Priveterra Acquisition Corp.

                          Deal Size : $276.0 million

                          Deal Type : Merger

                          blank

                          10

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The net funding will be used in the development of ABP-450 (prabotulinumtoxinA) which contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum, for the preventive treatment of episodic migraine.

                          Brand Name : ABP-450

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          June 30, 2023

                          Lead Product(s) : PrabotulinumtoxinA

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : $125.0 million

                          Deal Type : Financing

                          blank